NOVX’s Quick-Response Drug Test Gets 501(k) Clearance

imdx.jpgNOVX Systems, a venture-backed Canadian company working on technologies for addiction management, has received 501(k) clearance for its iMDx System for point-of-care drug testing. iMDx can run up to 140 urine tests per batch, and has cartridge-based reagents and the ability to accommodate standard sample cups. The unit, which can be set up for use in about five minutes, can analyze 14 urine samples in just over an hour, eliminating long waits for results. Through NOVX’s other product, PatientVu, a software suite for managing addiction patients, drug screening results from iMDx are accessible online.

NOVX’s last round of funding took place in March 2005, when it completed a Series B financing led by The Growth Fund, and joined by first-round investors Celtic House, CMEA and Storm Ventures. In August 2006, it completed an extension of that round.

The comments are closed.